Article
Multidisciplinary Sciences
K. C. Nicolaou, Stephan Rigol, Emmanuel N. Pitsinos, Dipendu Das, Yong Lu, Subhrajit Rout, Alexander W. Schammel, Dane Holte, Baiwei Lin, Christine Gu, Hetal Sarvaiya, Jose Trinidad, Nicole Barbour, Amanda M. Valdiosera, Joseph Sandoval, Christina Lee, Monette Aujay, Hanan Fernando, Anukriti Dhar, Holger Karsunky, Nicole Taylor, Marybeth Pysz, Julia Gavrilyuk
Summary: ADCs have shown strong efficacy as targeted anticancer therapeutics, particularly with enediyne DNA-damaging payloads such as uncialamycin, displaying high selectivity and cytotoxicity in vitro and in vivo.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Biotechnology & Applied Microbiology
Kazuomi Takahashi, Hirotoshi Yasui, Shunichi Taki, Misae Shimizu, Chiaki Koike, Kentaro Taki, Hiroshi Yukawa, Yoshinobu Baba, Hisataka Kobayashi, Kazuhide Sato
Summary: This article describes a drug-ADC created through double conjugation that can be released by light and used for targeted treatment of tumor cells. The technology has shown anti-tumor effects both in vitro and in vivo, and has potential for targeting different specific cancer antigens.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2022)
Review
Oncology
Federica Giugliano, Chiara Corti, Paolo Tarantino, Flavia Michelini, Giuseppe Curigliano
Summary: This review summarizes the current preclinical and clinical evidence about the bystander effect of antibody-drug conjugates (ADCs) in solid tumors. Recent findings suggest that the bystander killing effect of certain ADCs, which involves the unintended diffusion of the drug payload from antigen-positive tumor cells to adjacent antigen-negative tumor cells, may overcome the challenge of heterogeneous antigen expression. Further research is needed to determine if the bystander effect is necessary for achieving solid activity with ADCs.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Pharmacology & Pharmacy
Giulia Pander, Philipp Uhl, Nikos Kuehl, Uwe Haberkorn, Jan Anderl, Walter Mier
Summary: Antibody-drug conjugates (ADCs) are a new type of drug widely used in targeted cancer treatment. By guiding highly toxic compounds to target cells, ADCs can reduce damage to healthy cells. Recent research has focused on stimulating immune responses to induce immunogenic cell death and influencing the tumor microenvironment to enhance treatment effects.
DRUG DISCOVERY TODAY
(2022)
Article
Chemistry, Medicinal
Xinyue Hu, Hailun Jiang, Weiqi Bai, Xiujun Liu, Qingfang Miao, Linlin Wang, Jie Jin, Along Cui, Rui Liu, Zhuorong Li
Summary: ADCs, composed of a monoclonal antibody and warhead, are a successful strategy for treating solid tumors. Novel linker-MMAE conjugates showed increased activity for some ADCs and potential for treating other types of cancer.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Lars Guelen, Thierry O. Fischmann, Jerelyn Wong, Smita Mauze, Marco Guadagnoli, Nikolina Babala, Jozef Wagenaars, Veronica Juan, David Rosen, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Judith Stammen-Vogelzangs, Ying Yu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Yiwei Zhang, Richard Wnek, Sean Troth, Elliot Chartash, Konstantin Dobrenkov, Svetlana Sadekova, Andrea van Elsas, Jason K. Cheung, Laurence Fayadat-Dilman, Jannie Borst, Amy M. Beebe, Hans Van Eenennaam
Summary: MK-5890, a novel CD27 agonistic antibody, has the potential to complement PD-1 checkpoint inhibition in cancer immunotherapy and is currently undergoing clinical evaluation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Aiko Yamaguchi, Yasuaki Anami, Summer Y. Y. Ha, Travis J. Roeder, Wei Xiong, Jangsoon Lee, Naoto T. Ueno, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
Summary: Researchers developed and evaluated bispecific ADCs chemically functionalized with tumor-targeting small molecules, which can simultaneously target two different cancer antigens. These ADCs showed good stability and potential for effectively treating tumors with heterogeneous antigen expression.
BIOORGANIC & MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Rong Huang, Yao Sheng, Zili Xu, Ding Wei, Xiaoling Song, Biao Jiang, Hongli Chen
Summary: The natural product combretastatin A4 (CA4) has been identified as a versatile new payload for antibody-drug conjugates (ADCs), showing high potency against cancer cells and significant antitumor activities in EGFR-positive xenograft models. This research suggests that CA4 is a viable option for ADCs research and development.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Review
Oncology
Mo Wu, Wei Huang, Nan Yang, Yanyong Liu
Summary: Chemotherapy is criticized for its non-selective toxicity and drug resistance. Combination therapy, such as drug conjugates, has been developed to improve clinical efficacy. Compared to antibody-drug conjugates, peptide-drug conjugates have advantages but also face limitations in development.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Cynthia Mark, Jin Sun Lee, Xiaojiang Cui, Yuan Yuan
Summary: Antibody drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic drugs for selective delivery to cancer cells, optimizing treatment effectiveness. ADC research has significantly impacted breast cancer management, providing valuable options. However, important questions remain, such as drug sequencing and overcoming resistance mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Anne Tvilum, Mikkel Johansen, Laerke N. Glud, Diana M. Ivarsen, Amanda B. Khamas, Sheiliza Carmali, Snehit Satish Mhatre, Ane B. Sogaard, Emma Faddy, Lisanne de Vor, Suzan H. M. Rooijakkers, Lars Ostergaard, Nis P. Jorgensen, Rikke L. Meyer, Alexander N. Zelikin
Summary: In this study, antibody-drug conjugates (ADCs) containing mitomycin C, an anti-neoplastic drug with antimicrobial properties, were engineered to target bacteria in biofilms. The ADCs released the drug without entering the bacterial cells, likely through interaction with thiols on the bacterial cell surface. The targeted ADCs showed superior antimicrobial effects compared to non-specific counterparts in vitro, in biofilms, and in an in vivo osteomyelitis model. These findings have significant translational potential for the development of ADCs as a treatment for bacterial biofilm infections.
Article
Chemistry, Multidisciplinary
Syeda Warisul Fatima, Sunil K. Khare
Summary: ADCs are a new therapeutic approach that combines chemotherapy and immunotherapy, delivering cytotoxic molecules to cancer cells through monoclonal antibodies. Research reviews how to enhance ADCs efficiency and the promising prospects of antibody conjugated nanoparticles (ACNPs) in targeted drug delivery to cancer cells.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Chemistry, Analytical
Yutaka Matsuda
Summary: Antibody-drug conjugates have gained attention for their expanded therapeutic index compared to traditional chemotherapies, but their complex structure requires strict control of critical quality attributes during manufacturing. The future landscape of antibody-conjugates field remains to be further explored.
JOURNAL OF SEPARATION SCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Yanchen Li, Ru Si, Jin Wang, Ping Hai, Yongbiao Zheng, Qingqing Zhang, Xiaoyan Pan, Jie Zhang
Summary: Bevacizumab is an FDA-approved monoclonal antibody used to inhibit angiogenesis and promote blood vessel normalization. In this study, a bevacizumab-based antibody-drug conjugate called Bevacizumab Vedotin was designed and shown to have strong stability and tumor cell targeting. It exhibited anti-proliferative, apoptosis-promoting, and cell cycle-stalling effects on various cancer cell lines, and demonstrated enhanced anti-migration and anti-angiogenic activity.
BIOORGANIC CHEMISTRY
(2023)
Review
Chemistry, Medicinal
Ahmad Hussain, Armin Grimm, Wenjie Sheng, Chaoyu Zhang, Marwah Al-Rawe, Karen Braeutigam, Mobarak Abu Mraheil, Felix Zeppernick, Ivo Meinhold-Heerlein
Summary: Antibodies have revolutionized cancer treatment with their unique ability to recognize specific antigens and various therapeutic mechanisms. Modification techniques have allowed for the development of new antibody-conjugate-based diagnostic and therapeutic agents, but overcoming the heterogeneity generated by bioconjugation approaches remains a challenge. This review highlights enzyme-based site-specific conjugation methods to improve antibody properties.